IMR Press / RCM / Volume 5 / Issue S5 / pii/1561344995352-1141396268

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Ximelagatran: Pharmacokinetics and Pharmacodynamics of a New Strategy for Oral Direct Thrombin Inhibition
Show Less
1 The Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, OH
Rev. Cardiovasc. Med. 2004, 5(S5), 4–11;
Published: 20 November 2004
Abstract
Because thrombin is central to the development and propagation of both arterial and venous thrombi, it is a logical therapeutic target. Direct thrombin inhibitors, such as ximelagatran, offer the distinct advantage of inhibiting fibrin-bound as well as free thrombin. The pharmacokinetics and pharmacodynamics of ximelagatran are predictable across a broad spectrum of patients. The half-life of melagatran, ximelagatran's active metabolite, is consistent with twice-daily dosing and fixed-dose administration without the need for monitoring. There have been no known drug interactions with ximelagatran, and the agent is not metabolized by the hepatic cytochrome P-450 system. For these reasons, orally active direct thrombin inhibitors such as ximelagatran will likely become the standard for long-term anticoagulation.
Keywords
Melagatran
Pharmacodynamics
Pharmacokinetics
Thrombin
Ximelagatran
Share
Back to top